STOCK TITAN
  1. Home
  2. Sec-filings
  3. DRTS
  4. [6-K] Alpha Tau Medical Ltd. Current Report (Foreign Issuer)

Alpha Tau (Nasdaq: DRTS) ASCO abstract pools 58 pancreatic cancer patients

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. is highlighting new pancreatic cancer research based on its Alpha DaRT® radiation therapy. An abstract combining safety and efficacy data from 58 patients across three prospective pancreatic cancer studies in Canada and Israel has been accepted for presentation at the 2026 ASCO Annual Meeting, a major global oncology conference. The pooled analysis covers endoscopic ultrasound-guided intratumoral Alpha DaRT in locally advanced or metastatic pancreatic ductal adenocarcinoma and reflects growing scientific interest in the company’s pancreatic cancer program, alongside ongoing IMPACT and ACAPELLA clinical trials.

Positive

  • None.

Negative

  • None.
Patients in pooled analysis 58 patients Combined across three prospective Alpha DaRT pancreatic studies
ASCO Annual Meeting dates May 29 - June 2, 2026 Conference hosting Alpha Tau’s pancreatic abstract
Abstract online publication time May 21, 2026 at 5:00 PM ET ASCO website publication of Alpha Tau pancreatic abstract
Alpha DaRT medical
"Alpha Tau Medical Ltd. … the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®"
pancreatic ductal adenocarcinoma medical
"patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)"
A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.
endoscopic ultrasound (EUS)-guided intratumoral medical
"evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment"
IMPACT trial medical
"Our flagship multicenter IMPACT trial in the United States continues to advance"
ACAPELLA trial medical
"we recently treated the first patient in April in the ACAPELLA trial"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did Alpha Tau Medical Ltd. (DRTS) announce in this 6-K filing?
Alpha Tau announced that an abstract on its Alpha DaRT pancreatic cancer program was accepted for presentation at the 2026 ASCO Annual Meeting, highlighting pooled safety and efficacy data from three clinical studies involving 58 patients in Canada and Israel.

What pancreatic cancer data is Alpha Tau (DRTS) presenting at ASCO 2026?
Alpha Tau will present a pooled analysis titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer,” covering 58 patients treated with endoscopic ultrasound-guided intratumoral Alpha DaRT for locally advanced or metastatic pancreatic ductal adenocarcinoma.

When will Alpha Tau’s ASCO pancreatic cancer abstract be published online?
The abstract is expected to be published on the ASCO Annual Meeting website on May 21, 2026, at 5:00 PM ET, ahead of the conference scheduled from May 29 to June 2, 2026, providing detailed pancreatic Alpha DaRT clinical data.

How many patients were included in Alpha Tau’s pooled Alpha DaRT pancreatic analysis?
The pooled analysis combines safety and efficacy data from 58 patients with locally advanced or metastatic pancreatic ductal adenocarcinoma, treated across three prospective clinical studies at centers in Montreal, Canada and Jerusalem, Israel, using endoscopic ultrasound-guided intratumoral Alpha DaRT.

What other pancreatic cancer trials is Alpha Tau (DRTS) running with Alpha DaRT?
Alpha Tau’s pancreatic program includes the multicenter IMPACT trial in the United States, evaluating Alpha DaRT plus chemotherapy in newly diagnosed unresectable pancreatic cancer, and the ACAPELLA trial in France, studying Alpha DaRT with capecitabine for locally advanced pancreatic cancer.

Why is ASCO Annual Meeting acceptance important for Alpha Tau Medical Ltd.?
ASCO Annual Meeting acceptance follows a rigorous peer-review process and is widely seen as recognition of scientific merit. For Alpha Tau, it signals growing expert interest and validation of its Alpha DaRT pancreatic cancer clinical program, which now includes multiple international trials and pooled data.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

  

FORM 6-K

 

 

  

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2026

 

Commission File Number: 001-41316

 

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)  

 

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 
 

  

CONTENTS

 

On April 27, 2026, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

The information in this Report on Form 6-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

1

 

  

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release dated April 27, 2026.

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Alpha Tau Medical Ltd.
     
Date: April 27, 2026 By: /s/ Uzi Sofer
    Uzi Sofer
    Chief Executive Officer

 

 

3

 

 

Exhibit 99.1

 

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies

 

- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most prestigious medical oncology conference -

 

- Pooled analysis combines safety and efficacy data from 58 patients across three prospective clinical studies conducted at centers in Canada and Israel -

 

- Acceptance of abstract comes in the same year as presentations at the ASCO Gastrointestinal Cancers Symposium and at Digestive Disease Week (DDW), reflecting growing interest within the expert scientific community in Alpha DaRT pancreatic cancer clinical data -

  

- Abstract to be published on ASCO conference website on May 21, 2026, at 5:00 PM ET -

 

Jerusalem, April 27, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that an abstract entitled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer” has been accepted at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026. The abstract is expected to be published on May 21, 2026, at 5:00 PM ET on the ASCO conference website at https://www.asco.org/annual-meeting.

 

The ASCO Annual Meeting is widely regarded as the largest and most prestigious medical oncology conference in the world, attracting tens of thousands of leading oncologists, researchers, and healthcare professionals from across the globe. Abstract acceptance at ASCO is determined through a rigorous, peer-review process and represents recognition of the scientific merit and clinical relevance of the submitted research.

 

The abstract presents a pooled analysis of safety and efficacy data from three prospective clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The studies were conducted at the Jewish General Hospital and Centre Hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada, and at the Hadassah Medical Center in Jerusalem, Israel, enrolling a combined total of 58 patients. Acceptance of the abstract at the ASCO Annual Meeting, together with abstract presentation at ASCO GI and Digestive Disease Week (DDW) this year, underscores the growing scientific interest and momentum behind the Alpha DaRT pancreatic cancer program.

 

Uzi Sofer, CEO of Alpha Tau, stated, “The acceptance of an abstract at the ASCO Annual Meeting is a wonderful milestone for Alpha Tau and a powerful endorsement of our pancreatic cancer strategy by some of the most prestigious leaders in the field. The continued recognition of our clinical program reflects the growing maturity and strength of our evidence base, and validates the strategic vision behind our multi-study approach to pancreatic cancer: to build one of the most comprehensive intratumoral radiotherapeutic clinical programs in pancreatic cancer worldwide.”

 

Corey Miller, MD, MSc, Director of Therapeutic Endoscopy of the Division of Gastroenterology at the Jewish General Hospital, Assistant Professor of Medicine at McGill University, and the first and presenting author of the abstract, commented, “As the first physician to deliver Alpha DaRT into the pancreas using an endoscopic ultrasound-guided approach, it is deeply meaningful to see how far this program has come. What began as a first-in-human feasibility procedure has evolved into a robust clinical data set, made possible by the close collaboration between gastroenterology, medical oncology and radiation oncology teams. It is this combined effort that enabled the accrual of this cohort and the generation of comprehensive results now accepted at the world’s foremost oncology conference. The EUS-guided intratumoral approach has proven to be technically feasible and well-integrated into clinical workflows, and we look forward to sharing these findings with the global medical community when the abstract is published by ASCO and in the Journal of Clinical Oncology.”

 

Robert B. Den, MD, Chief Medical Officer of Alpha Tau stated, “This ASCO acceptance is a significant validation of our growing pancreatic cancer clinical program at a critical time. The pooled analysis provides a strong foundation of clinical evidence, and we are actively building on this momentum. Our flagship multicenter IMPACT trial in the United States continues to advance, evaluating Alpha DaRT in combination with chemotherapy in patients with newly diagnosed unresectable pancreatic cancer. In addition, we recently treated the first patient in April in the ACAPELLA trial - a multicenter study in France evaluating Alpha DaRT alongside capecitabine in patients with locally advanced pancreatic cancer. Together, these studies represent an expanding and increasingly global clinical pipeline dedicated to addressing one of the most significant unmet needs in oncology.”

 

About Alpha DaRT®

 

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal intratumoral treatment of solid tumors. Alpha DaRT sources are inserted directly into the tumor, where they release short-lived therapeutic particles that disperse locally with the goal of destroying the tumor. Since the therapeutic effect is confined to a short distance, Alpha DaRT aims to mainly affect the tumor and to spare the healthy tissue around it.

 

 

 

 

About Alpha Tau Medical Ltd.

 

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

 

Forward-Looking Statements

 

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic patients, including the potential benefits and associated risks, future applications and uses, the IMPACT study, the ACAPELLA study, timing of the abstract publication, and potential indication approvals, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

 

Investor Relations Contact:

IR@alphatau.com

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases